title: Intralesional interferon alpha-2b therapy for Buschke-Loewenstein tumour.
abstract: A patient with a Buschke-Loewenstein tumour associated with human papillomavirus type 6/11 is reported. He was intralesionally treated with human recombinant alpha-2b interferon (9 x 10(6) IU/day) three times weekly. The tumour completely disappeared within 5 months of continuous treatment which was well tolerated. Sixteen months after completion of therapy the patient remains well and free of disease.
authors.affiliation: Department of Dermatology, University of Patras, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Tsambaos
authors.forename: A
authors.initials: A
authors.lastname: Monastirli
authors.forename: N
authors.initials: N
authors.lastname: Kapranos
authors.forename: S
authors.initials: S
authors.lastname: Georgiou
authors.forename: E
authors.initials: E
authors.lastname: Pasmatzi
authors.forename: H
authors.initials: H
authors.lastname: Berger
mesh_terms: D000328:Adult; D003218:Condylomata Acuminata / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006119:Groin; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins; D012074:Remission Induction; D012871:Skin Diseases / Q000473:pathology / Q000628:therapy*; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins